NICE - Endorsed Technology Appraisals 2017/2018
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2017/2018
The following technology appraisals have been endorsed during 2017/18. Information on technology appraisals endorsed in previous years can be found on the homepage.
Fully Endorsed
March 2018
- NICE TA 504 - Pirfenidone for treating idiopathic pulmonary fibrosis
- This guidance updates and replaces NICE Technology Appraisal TA282, which was endorsed by the DoH in May 2013NICE TA
- NICE TA 506 - Lesinurad for treating chronic hyperuricaemia in people with gout
- NICE TA 507 - Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
- NICE TA 508 - Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
- NICE TA 509 - Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
- NICE TA 526 - Arsenic trioxide for treating acute promyelocytic leukaemia
February 2018
- NICE TA 498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
- NICE TA 499 - Glecaprevir–pibrentasvir for treating chronic hepatitis C
- NICE TA 500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer
- NICE TA 501 - Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
- NICE TA 502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
- NICE TA 503 - Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
January 2018
- NICE TA 495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE TA 496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE TA 497 - Golimumab for treating non-radiographic axial spondyloarthritis
December 2017
- NICE TA 488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
- NICE TA 489 - Vismodegib for treating basal cell carcinoma
- NICE TA 193 - Cladribine tablets for treating relapsing-remitting multiple sclerosis
- Note this guidance has been updated and replaced by TA616 - Cladribine for treating relapsing–remitting multiple sclerosis, which was endorsed by the DoH in January 2020.
- NICE TA 494 - Naltrexone–bupropion for managing overweight and obesity
November 2017
- NICE TA 480 - Tofacitinib for moderate to severe rheumatoid arthritis
- NICE TA 481 - Immunosuppressive therapy for kidney transplantation in adults (review of TA85)
- NICE TA 482 - Immunosuppressive therapy for kidney transplant in children and young people (review of TA99)
- NICE TA 485 - Sarilumab for moderate to severe rheumatoid arthritis
- NICE TA 486 - Aflibercept for treating choroidal neovascularisation
October 2017
- NICE TA 475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA 476 - Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (review of TA360)
- This guidance updates and replaces NICE Technology Appraisal TA360, which was endorsed by the DoH in November 2015.
- NICE TA 477 - Autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (review of TA89)
- NICE TA 478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
- NICE TA 479 - Reslizumab for treating severe eosinophilic asthma
September 2017
- NICE TA 463 - Cabozantinib for previously treated advanced renal cell carcinoma
- NICE TA 464 - Bisphosphonates for treating osteoporosis
- This guidance partially updates TA160 - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and TA161 - Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, which were endorsed by DoH in June 2009.
- NICE TA 466 - Baricitinib for moderate to severe rheumatoid arthritis
- NICE TA 467 - Holoclar for treating limbal stem cell deficiency after eye burns
- NICE TA 471 - Eluxadoline for treating irritable bowel syndrome with diarrhoea
- NICE TA 473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (review of TA172)
- This guidance updates and replaces NICE Technology Appraisal TA172, which was endorsed by the DoH in November 2009.
- NICE TA 474 - Sorafenib for treating advanced hepatocellular carcinoma (review of TA189)
- Note this guidance updates and replaces NICE Technology Appraisal TA189, which was endorsed by the DoH in March 2011.
August 2017
- NICE TA 455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA 456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA 457 - Carfilzomib for previously treated multiple myeloma Note this guidance has been updated and replaced by TA657 - Carfilzomib for previously treated multiple myeloma, which was endorsed by the DoH in December 2020.
- NICE TA 458 - Trastuzumab emtansine for treating HER2 positive advanced breast cancer after trastuzumab and a taxane (review of TA371)
- Note this guidance updates and replaces NICE Technology Appraisal TA371, which was endorsed by the DoH in January 2016
- NICE TA 459 - Collagenase clostridium histolyticum for treating Dupuytren’s contracture
- NICE TA 460 - Adalimumab and dexamethasone for treating non-infectious uveitis
- NICE TA 461 - Roflumilast for treating chronic obstructive pulmonary disease (review of TA244)
- Note this guidance updates and replaces NICE Technology Appraisal TA244, which was endorsed by the DoH in February 2012
- NICE TA 462 - Nivolumab for relapsed or refractory classical Hodgkin lymphoma
July 2017
- NICE TA 446 - Brentuximab vedotin for treating CD30-positive Hodgkin's lymphoma
This guidance has been updated and replaced by TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma, which was endorsed by the DoH in June 2018.
- NICE TA 448 - Etelcalcetide for treating secondary hyperparathyroidism
- NICE TA 449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE TA 450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- NICE 451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
June 2017
- NICE TA 445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- Note this guidance should be read in conjunction with NICE Technology Appraisal TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis, which was endorsed by DoH in December 2011.
May 2017
NICE TA 441 - Daclizumab for treating relapsing-remitting multiple sclerosis
- NICE TA 442 - Lxekizumab for treating moderate to severe plaque psoriasis
- NICE TA 443 - Obeticholic acid for treating primary biliary cholangitis
April 2017
- NICE TA 439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (review of TA176 & part review of TA240)
- This guidance updates and replaces NICE Technology Appraisal TA176, which was endorsed by the DoH in September 2010.